A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.

ABSTRACT: Extensive interindividual variation in response to chemotherapy is a major stumbling block in achieving desirable efficacy in the treatment of cancers, including multiple myeloma (MM). In this study, our goal was to develop a gene expression signature that predicts response specific to proteasome inhibitor (PI) treatment in MM. Using a well-characterized panel of human myeloma cell lines (HMCLs) representing the biological and genetic heterogeneity of MM, we created an in vitro chemosensitivity profile in response to treatment with the four PIs bortezomib, carfilzomib, ixazomib and oprozomib as single agents. Gene expression profiling was performed using next-generation high-throughput RNA-sequencing. Applying machine learning-based computational approaches including the supervised ensembl

SUBMITTER: Mitra AK 

PROVIDER: S-EPMC5520403 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature